IMC-C225
Showing 1 - 25 of 2,767
Chordoma, Metastatic Chordoma, Unresectable Chordoma Trial in Houston (Cetuximab, Questionnaire Administration)
Recruiting
- Chordoma
- +2 more
- Cetuximab
- Questionnaire Administration
-
Houston, TexasM D Anderson Cancer Center
Jun 1, 2022
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer Trial in Buffalo, Cleveland (Cetuximab,
Completed
- Recurrent Colorectal Carcinoma
- +2 more
- Cetuximab
- +2 more
-
Buffalo, New York
- +1 more
Sep 29, 2022
Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,
Not yet recruiting
- Metastatic Colorectal Adenocarcinoma
- +2 more
- BET Bromodomain Inhibitor ZEN-3694
- +6 more
- (no location specified)
Oct 25, 2023
Colon Cancer, Resected Stage Trial in Houston (Cetuximab, CB-NK-TGF-βR2-/NR3C1, Fludarabine phosphate)
Recruiting
- Colon Cancer
- Resected Stage
- Cetuximab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 23, 2022
Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8 Trial in Houston
Active, not recruiting
- Metastatic Colorectal Carcinoma
- +4 more
- Cetuximab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 4, 2022
BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Tumor Trial in Houston (biological, drug, other)
Active, not recruiting
- BRAF NP_004324.2:p.V600X
- +6 more
- Cetuximab
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck
Active, not recruiting
- Metastatic Head and Neck Squamous Cell Carcinoma
- +2 more
- Cetuximab
- +2 more
-
Washington, District of Columbia
- +1 more
Mar 25, 2022
Advanced Cancers Trial in Houston (Regorafenib, Cetuximab, Questionnaire)
Completed
- Advanced Cancers
- Regorafenib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Mar 31, 2021
BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma Trial in United States
Recruiting
- BRAF V600E Negative
- +12 more
- Cetuximab
- +3 more
-
Scottsdale, Arizona
- +15 more
Aug 23, 2022
Metastatic Colorectal Cancer Trial in Philadelphia (drug, biological, genetic, other)
Terminated
- Metastatic Colorectal Cancer
- fluorouracil
- +14 more
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Feb 22, 2021
Metastatic Colorectal Carcinoma, Metastatic Malignant Tumor in the Liver, Stage IV Colorectal Cancer AJCC v8 Trial (biological,
Not yet recruiting
- Metastatic Colorectal Carcinoma
- +3 more
- Bevacizumab
- +11 more
- (no location specified)
May 9, 2023
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell
Terminated
- Stage III Squamous Cell Carcinoma of the Hypopharynx
- +11 more
- cetuximab
- +3 more
-
Newark, New JerseyNew Jersey Medical School
Apr 19, 2021
Advanced Malignant Tumor, Castleman Disease, Digestive System Carcinoma Trial in Houston (biological, other, drug)
Active, not recruiting
- Advanced Malignant Neoplasm
- +38 more
- Bevacizumab
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive)
Recruiting
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- +4 more
- Cetuximab
- +4 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Oct 4, 2021
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma Trial in Houston
Recruiting
- Metastatic Colon Adenocarcinoma
- +30 more
- Abemaciclib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 24, 2022
Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7 Trial in United States (biological, drug, other)
Completed
- Colorectal Adenocarcinoma
- +4 more
- Bevacizumab
- +4 more
-
Scottsdale, Arizona
- +12 more
Jan 27, 2022
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With
Completed
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- +35 more
- PI3K inhibitor BKM120
- cetuximab
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
Sep 14, 2021
Head and Neck Tumors Trial in Saint Louis (drug, radiation, procedure)
Completed
- Head and Neck Neoplasms
- paclitaxel albumin-stabilized nanoparticle formulation
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Sep 9, 2020
Head and Neck Squamous Cell Carcinoma Trial in Houston (Cetuximab, IMC-A12, Surgical tumor resection)
Completed
- Head and Neck Squamous Cell Carcinoma
- Cetuximab
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Mar 18, 2020
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8 Trial in United States
Recruiting
- Metastatic Colon Adenocarcinoma
- +7 more
- Cetuximab
- +2 more
-
Bloomington, Illinois
- +70 more
Aug 6, 2022
Brain Tumor, Malignant Glioma Trial in Palo Alto (biological, drug, procedure)
Terminated
- Brain Neoplasm
- Malignant Glioma
- Cetuximab
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Mar 17, 2020
Colon Cancer, Colorectal Cancer Trial in Houston (MRTX849, Irinotecan, Cetuximab)
Not yet recruiting
- Colon Cancer
- Colorectal Cancer
- MRTX849
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Feb 1, 2023
Metastatic Colorectal Cancer Trial (Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6/FOLFIRI)
Not yet recruiting
- Metastatic Colorectal Cancer
- Cetuximab + Envafolimab + mFOLFOXIRI
- Cetuximab + mFOLFOX6/FOLFIRI
- (no location specified)
Jul 24, 2023